Trimetazidine may protect the myocardium during cardiac surgery

Simple item page
dc.contributor.authorIskesen I.
dc.contributor.authorKurdal A.T.
dc.contributor.authorEserdag M.
dc.contributor.authorCerrahoglu M.
dc.contributor.authorSirin B.H.
dc.date.accessioned2024-07-22T08:21:37Z
dc.date.available2024-07-22T08:21:37Z
dc.date.issued2009
dc.description.abstractBackground: Trimetazidine is an anti-ischemic agent with cardioprotective effects. The purpose of this double-blind, controlled, prospective randomized study was to investigate the possible effects of the preoperative use of trimetazidine on the biochemical markers of myocardial injury during open heart surgery and to determine if it has any myocardial protective effects. Methods: Thirty patients undergoing coronary artery bypass grafting surgery, received either trimetazidine (study group, n = 15) or not (control group, n = 15). Pretreatment began 2 weeks before the operation with trimetazidine (60 mg/day orally), and the control group received no medication. We measured the levels of serum creatine kinase (CK), CK isoenzyme MB (CK-MB), myoglobin, and troponin T in venous blood samples obtained before and after the operation to evaluate the effect of this drug against myocardial damage. We also took serial blood samples from the radial artery and the coronary sinus before the institution of cardiopulmonary bypass (CPB) and at 2 and 15 minutes after the removal of the cross-clamp to measure lactate levels and calculate the lactate extraction of the myocardium. Results: Postoperative levels of myoglobin, troponin T, CK, and CK-MB were significantly lower in the trimetazidine group than in the control group (P < .05). There was also a significant difference in the values for the lactate extraction calculation between the groups at minute 2 after the removal of the cross-clamp (P < .05). Conclusion: We conclude that pretreatment with trimetazidine has some beneficial effects in protecting the myocardium and decreasing myocardial injury during the cardioplegic arrest period in open heart surgery without affecting postoperative hemodynamics. © 2009 Forum Multimedia Publishing, LLC.
dc.identifier.DOI-ID10.1532/HSF98.20081133
dc.identifier.issn15226662
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18697
dc.language.isoEnglish
dc.subjectCardiotonic Agents
dc.subjectCoronary Artery Bypass
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyocardial Ischemia
dc.subjectTreatment Outcome
dc.subjectTrimetazidine
dc.subjectVasodilator Agents
dc.subjectcreatine kinase
dc.subjectcreatine kinase MB
dc.subjectlactic acid
dc.subjectmyoglobin
dc.subjecttrimetazidine
dc.subjecttroponin T
dc.subjectcardiotonic agent
dc.subjecttrimetazidine
dc.subjectvasodilator agent
dc.subjectadult
dc.subjectarticle
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcoronary artery bypass graft
dc.subjectdouble blind procedure
dc.subjectdrug activity
dc.subjectenzyme blood level
dc.subjectfemale
dc.subjectheart muscle
dc.subjectheart muscle injury
dc.subjectheart protection
dc.subjecthemodynamics
dc.subjecthuman
dc.subjectmale
dc.subjectpriority journal
dc.subjectprotein blood level
dc.subjectrandomized controlled trial
dc.subjecttissue level
dc.subjectcoronary artery bypass graft
dc.subjectheart muscle ischemia
dc.subjectmiddle aged
dc.subjecttreatment outcome
dc.titleTrimetazidine may protect the myocardium during cardiac surgery
dc.typeArticle

Files

Collections

Scopus Koleksiyonu